INTRODUCTION {#h0.0}
============

Ebola virus (EBOV) and Marburg virus (MARV) are both members of the *Filoviridae* family of enveloped negative-strand RNA viruses and are the causative agents of a highly lethal disease for which no approved vaccines or treatments are currently available ([@B1], [@B2]). Due to their virulence and biothreat potential, filoviruses are classified as category A pathogens. The ongoing EBOV epidemic in West Africa is the longest and most widespread filovirus outbreak on record ([@B3]).

Like all filoviruses, EBOV displays a single virus-encoded protein, the viral glycoprotein (GP), on the surface of the virion. EBOV GP is a 676-residue class I membrane fusion glycoprotein. However, EBOV GP differs from canonical class I fusion proteins, such as those of human immunodeficiency virus and influenza A virus, in that the architecture of its fusion loop more closely resembles those of class II and III glycoproteins ([@B4], [@B5]). EBOV GP is synthesized as a precursor polypeptide, GP~0~, which assembles into trimers in the endoplasmic reticulum. Each GP~0~ subunit is then posttranslationally cleaved by the Golgi endoprotease furin to yield disulfide-linked GP~1~ (≈55 kDa) and GP~2~ (≈20 kDa) subunits. The final GP assembly, which is an ≈450 kDa trimer of GP~1,2~ heterodimers, is then displayed on the surface of mature EBOV virions ([@B4], [@B5]). GP~1~ contains the receptor-binding site and regulates the triggering of the membrane fusion machinery in the GP~2~ subunit ([@B6]).

The GP~1~ structure can be divided into three subdomains: the mucin domain, glycan cap, and GP~1~ core. The outer mucin domain (GP~1~ residues 313 to 464), is predicted to be loosely structured and heavily glycosylated, incorporating five N-linked glycans and 12 to 17 predicted O-linked glycans ([@B5]). Interior to the mucin-like domain is the glycan cap (GP~1~ residues 227 to 313), which sits atop the GP~1~ core. The glycan cap is more ordered than the mucin-like domain and contains four N-linked glycosylation sites. Neither the mucin nor the glycan cap domain is essential for viral entry. Indeed, removal of these domains enhances infection by viruses pseudotyped with EBOV GP ([@B7][@B8][@B9]). Therefore, it is currently hypothesized that a primary function of the mucin domain and glycan cap is to shield the GP~1~ core from immune surveillance ([@B4], [@B5], [@B10], [@B11]).

EBOV virions are internalized into cells via a macropinocytosis-like mechanism and undergo trafficking to late endosomes ([@B12][@B13][@B15]). There, host endosomal cysteine proteases, including cathepsins L (CatL) and B (CatB), cleave GP~1~ to remove the mucin and glycan cap domains. Cleavage generates a fusion-competent GP trimer (GP~CL~) comprising the 19-kDa GP~1~ core domain and GP~2~ ([@B8], [@B9], [@B16]). Cleavage of GP~1,2~ to GP~CL~ is a prerequisite for viral recognition of the host endosomal receptor Niemann-Pick C1 (NPC1) ([@B10], [@B17][@B18][@B20]), strongly suggesting that the receptor-binding site in the GP~1~ core structure is unmasked by the cleavage of GP~1~ in late endosomes. Thus, GP~CL~ represents the structure of EBOV GP in a conformation that is competent for receptor binding.

In order to observe possible structural changes in GP~CL~ and to illustrate definitively which surfaces and residues are unveiled upon endosomal proteolysis, we determined the crystal structure of the EBOV GP~CL~ trimer at a resolution of 3.3 Å, in complex with the neutralizing human antibody Fab KZ52 ([@B21]). We found that the main feature exposed upon priming of EBOV GP is a wave-like morphology at the top of GP~CL~, with a polar/basic crest rising above a large, recessed, hydrophobic trough, previously occupied by the glycan cap prior to priming by host cathepsins. Extensive structure-directed mutagenesis of EBOV GP~CL~ revealed that the basic character of the polar crest is crucial to the EBOV-receptor interaction, likely because it confers an initial electrostatic attraction between GP~CL~ and the second luminal domain of NPC1, domain C. We also find that the trough makes specific hydrophobic contacts that are essential to high-affinity GP~CL~-NPC1 domain C binding. Finally, we demonstrate that host-programmed unmasking of the NPC1-binding site in EBOV GP creates a broadly conserved target for neutralization by monoclonal antibodies (MAbs) recently isolated from a human survivor of MARV infection ([@B22]). Our results thus suggest a novel approach for developing engineered MAbs with broad-spectrum activity against filoviruses.

RESULTS {#h1}
=======

The crystal structure of EBOV GP~CL~ reveals the NPC1 receptor-binding site that is unmasked upon endosomal cleavage. {#s1.1}
---------------------------------------------------------------------------------------------------------------------

Purified EBOV GP~1,2~ ectodomains (expressed without mucin-like domains; hereinafter referred to as GP) were treated with thermolysin, which mimics host endosomal protease processing of EBOV GP ([@B8]), in order to generate EBOV GP~CL~ trimers for crystallization. EBOV GP~CL~ crystallizes in the space group H3 (R3:H) with four GP monomers and four KZ52 Fabs in the asymmetric unit (ASU). The ASU contains one full GP trimer and one remaining GP monomer, which itself forms a biologically relevant trimer with two symmetry-related protomers about a crystallographic 3-fold axis. The overall changes to the tertiary structure upon cleavage of GP are minimal, reflected in a root mean square deviation (RMSD) of 0.419 Å compared to the structure of uncleaved EBOV GP ([Fig. 1A](#fig1){ref-type="fig"}) ([@B4]). This finding corroborates a previous model of EBOV GP~CL~ which suggested only limited changes in the GP~CL~ structure upon thermolysin digestion ([@B23]). The structure of EBOV GP~CL~ is more compact than that of EBOV GP and exhibits more stable crystal packing, less disorder, and improved resolution of X-ray diffraction over that of the previously determined uncleaved GP ([@B4]).

![Crystal structure of ebolavirus GP~CL~. (A) The trimeric EBOV GP~CL~ structure is shown, with GP~1~ colored teal, GP~2~ colored light blue, the fusion loop colored orange, and disulfide bonds displayed as sticks and colored gold. The former position of the glycan cap, now absent in the GP~CL~ structure, is illustrated in semitransparent red and is derived from an alignment with the uncleaved EBOV GP structure (PDB code [3CSY](http://www.rcsb.org/pdb/explore/explore.do?structureId=3CSY)). (B) Additional residues at the C terminus of GP~2~ are now visible in this higher-resolution structure. These residues include C601-C608, contained within GP~2~, as well as the C53-C609 disulfide bond that cross-links GP~1~ and GP~2~ together. (C) The structure of EBOV GP~CL~ is displayed to the right, with the same coloring as described for panel A. An enlarged illustration of the putative EBOV GP~1~ RBS is shown to the left, in two orientations. Residues forming the hydrophilic crest and hydrophobic trough are labeled and colored green and purple, respectively. The disulfide bonds present around the crest and trough, C108-C135 and C121-C145, are colored gold.](mbo0011626960001){#fig1}

New regions of EBOV GP can now be visualized in the EBOV GP~CL~ structure. These include C-terminal residues of GP~2~, the disulfide link between C53 of GP~1~ and C609 of GP~2~, and an intra-GP~2~ disulfide bond between C601 and C610. As EBOV GP~2~ descends from the base of the GP trimer structure, it forms a tightly ordered loop structure that is stabilized by the intra-GP~2~ disulfide bond between C601 and C610. This disulfide link turns the peptide chain back toward the body of GP where it is anchored to GP~1~ by the C53-C609 inter-GP~1,2~ disulfide bond prior to turning downward toward the transmembrane domain and viral membrane ([Fig. 1B](#fig1){ref-type="fig"}).

The most striking structural feature of GP~CL~ is the full exposure of a charged hydrophilic crest and a large hydrophobic trough structure in immediate proximity to the GP~2~ fusion loop. The trough becomes exposed upon proteolytic excision of the glycan cap from EBOV GP and is 13 Å wide, 23 Å long, and 10 Å deep ([Fig. 1C](#fig1){ref-type="fig"}). Residues I113 and L111 form an exposed hydrophobic face inside the trough, while residues V79, T83, W86, F88, L122, V141, and I170 line the bottom of the trough.

Mutation of GP residues exposed after removal of the glycan cap affects viral infectivity and binding to the filovirus receptor NPC1. {#s1.2}
-------------------------------------------------------------------------------------------------------------------------------------

Previous work utilizing scanning mutagenesis of EBOV GP identified multiple residues important for viral infectivity ([@B24][@B25][@B26]). These studies were carried out prior to the availability of a crystal structure of EBOV GP ([@B4]) or GP~CL~ (this work) and prior to identification of the endosomal receptor, NPC1 ([@B17], [@B18]). Here, we map these residues onto the crystal structure of EBOV GP~CL~ and determine whether mutations in EBOV GP that reduce infectivity specifically correlate with defects in GP~CL~-NPC1 binding. Previous work identified three lysines at positions 114, 115, and 140 ([@B16], [@B25]) and hydrophobic residues F88, L111, and L122 ([@B25][@B26][@B27]) for which mutation to alanine diminishes infectivity ([@B16], [@B25]). These deficits in infectivity correlate with reductions in NPC1 binding, as determined by coimmunoprecipitation ([@B28]).

The crystal structure of EBOV GP~CL~ illustrates that K114, K115, and K140 lie along the crest and F88, L111, and L122 line the trough of EBOV GP~CL~. These hydrophobic residues are buried in uncleaved EBOV GP ([@B4]) but become solvent exposed in the trough of EBOV GP~CL~. We systematically mutated residues that the GP~CL~ crystal structure shows to be surface-exposed after cleavage, in order to determine their importance for NPC1 binding and viral infectivity and to define the GP~1~ receptor-binding site (RBS).

We pseudotyped vesicular stomatitis virus (VSV) particles with 73 mutant GP proteins and tested them for viral incorporation of GP relative to the incorporation of the wild-type (WT) protein, and for binding to the conformational antibody KZ52 ([@B4], [@B21]), which only recognizes properly folded GP (see [Fig. S4](#figS4){ref-type="supplementary-material"} in the supplemental material). The 68 VSV-GP mutants that met these quality benchmarks were then evaluated for their capacity to recognize a purified, soluble form of human NPC1 domain C in an enzyme-linked immunosorbent assay (ELISA), as described previously ([@B27], [@B29]). We report that WT EBOV GP~CL~ binds to NPC1 domain C with a 50% effective concentration (EC~50~) of ≈0.5 nM, consistent with a high-avidity binding interaction between these proteins. In comparison, we find that mutants that demonstrate reduced infectivity are also defective for binding to NPC1 domain C (see [Fig. S1](#figS1){ref-type="supplementary-material"} and [S2](#figS2){ref-type="supplementary-material"} in the supplemental material). Furthermore, a few single point mutations that cause drastic reductions (\>10-fold) in the GP~CL~-NPC1 domain C-binding EC~50~ are located in or around the hydrophobic trough and hydrophilic crest. These mutants allow us to map those residues of EBOV GP~1~ that are critical to NPC1 domain C onto the EBOV GP~CL~ structure and to better define the RBS (see [Fig. S1](#figS1){ref-type="supplementary-material"} and [S2](#figS2){ref-type="supplementary-material"}). Interestingly, mutation to alanine of two trough residues, F88 and L111, reduces viral infectivity dramatically (by \>3 log~10~ units) but has more modest effects on GP~CL~-NPC1 binding (see [Fig. S2A](#figS2){ref-type="supplementary-material"}). The disparity between strong reduction in infectivity but modest effect on NPC1 binding suggests that these residues may be important for steps in viral entry post-NPC1 binding and prior to membrane fusion, such as conformational changes or release of GP2.

The hydrophobic trough exposed on GP1 upon endosomal cleavage is the primary binding site of NPC1 domain C. {#s1.3}
-----------------------------------------------------------------------------------------------------------

We performed further mutagenesis of the hydrophobic trough to better define its precise role. Since most of the point mutations to alanine within the hydrophobic trough had only modest effects, we postulated that replacing them with bulkier methionine residues would more completely occlude the trough and prevent GP-NPC1 binding. We selected two trough residues, T83 and I113, which did not inhibit NPC1 binding when mutated to alanine, for additional mutagenesis to methionine ([Fig. 2A](#fig2){ref-type="fig"} and [B](#fig2){ref-type="fig"}). To prevent misfolding or disruption of the GP structure, we engineered compensatory mutations with interacting residues of the glycan cap to fit the larger methionine residues and prevent steric clashing. We engineered the following mutants: I113M (trough)/F225A (cap), T83M (trough)/F225V+Y232F (cap), and T83M+I113M (trough)/F225A+Y232F (cap) ([Fig. 2C](#fig2){ref-type="fig"} to [E](#fig2){ref-type="fig"}). For simplicity, since the compensatory mutations are removed along with the glycan cap upon proteolysis, we will only refer to these mutants by the mutations remaining on EBOV GP~CL~: T83M, I113M, and T83M+I113M. All engineered VSV-GP mutants maintain high levels of incorporation compared to the incorporation of WT GP (see [Fig. S2](#figS2){ref-type="supplementary-material"} in the supplemental material). As posited, the single T83M and I113M mutations, as well as the T83M+I113M double mutation, lead to defects in NPC1 domain C binding and pseudovirus infectivity by GP~CL~ bearing them ([Fig. 2A](#fig2){ref-type="fig"} to [C](#fig2){ref-type="fig"}). We further find that a single point mutation, L122A, located in the bottom of the trough, abrogates both NPC1 domain C binding and pseudotyped virus infectivity ([Fig. 2E](#fig2){ref-type="fig"}). The position of L122 suggests that it has a structural role; the L122A mutation may destabilize the local trough structure, preventing NPC1 binding and subsequent infectivity. Together, these findings provide evidence that supports a direct correlation between NPC1 binding and infectivity and effectively maps the GP~CL~ trough as a critical component of the NPC1-binding site.

![Mutagenic occlusion of the EBOV GP~1~ receptor-binding site. (A) Alanine or methionine mutations were made to key residues in the RBS. The affinities of wild-type and mutant GP~CL~ for NPC1 domain C were analyzed via ELISA. Note that the L122A and T83M+I113M mutations significantly reduce binding to NPC1 domain C. Means ± SD (*n* = 4) from a representative experiment are shown. (B) Graph displaying titers of VSV pseudoviruses harboring GP~1~ RBS mutations. Means ± SD (*n* = 2--4) from a representative experiment are shown. (C) A semitransparent surface has been placed over the cartoon model of the WT RBS on EBOV GP~1~ to display the RBS pocket (within the dashed oval outline). Residues T83 and I113 are illustrated as sticks (black). (D) Model of EBOV RBS bearing the mutations T83M and I113M (red). The longer side chains of the introduced methionine residues fill the RBS pocket and likely prevent NPC1 domain C binding by occluding the NPC1 binding site. (E) The buried location of L122 (black) is displayed in the EBOV GP~1~ RBS. See also [Fig. S1](#figS1){ref-type="supplementary-material"}, [S2](#figS2){ref-type="supplementary-material"}, and [S4](#figS4){ref-type="supplementary-material"} in the supplemental material.](mbo0011626960002){#fig2}

An overall basic charge on the GP~1~ crest is required for GP binding to NPC1 domain C and viral infectivity. {#s1.4}
-------------------------------------------------------------------------------------------------------------

Experiments performed prior to the identification of the filovirus endosomal receptor NPC1 demonstrated that K114A, K115A, and K140A mutations (now mapped to the GP~CL~ crest) significantly reduce viral infectivity ([@B16], [@B25]). Here, we investigated whether the observed reductions in viral infectivity from these mutations correlate with defects in binding to NPC1 domain C. We show that while the individual mutations K114A and K115A have only modest effects (see [Fig. S1](#figS1){ref-type="supplementary-material"} and [S2](#figS2){ref-type="supplementary-material"} in the supplemental material), the double mutation (K114A+K115A) dramatically inhibits GP~CL~-NPC1 domain C binding and viral entry ([Fig. 3A](#fig3){ref-type="fig"} and [B](#fig3){ref-type="fig"}). In contrast, the K140A mutant showed no significant defect in viral infectivity or NPC1 domain C binding (see [Fig. S2](#figS2){ref-type="supplementary-material"}). To test the hypothesis that these crest residues participate in electrostatic interactions with NPC1 during virus-receptor engagement, we engineered and analyzed VSV-GPs in which these lysines were replaced with either basic or acidic residues. The K114R+K115R double mutant, which maintains the basic charge, remains fully functional. In contrast, the K114E+K115E double mutant, which reverses charge, displays an even greater deficit in receptor-binding function and entry activity than the neutral K114A+K115A mutant ([Fig. 3A](#fig3){ref-type="fig"} and [B](#fig3){ref-type="fig"}). To determine whether it is the overall charge of the site or specific basic residues within the site that are important, we mutated two glutamic acid residues in proximity to positions 114 and 115 to alanine. The resulting quadruple mutant (K114A+K115A+E112A+E120A), which is predicted to have WT-like electrostatics, exhibits receptor-binding activity and infectivity at nearly WT levels ([Fig. 3A](#fig3){ref-type="fig"} and [B](#fig3){ref-type="fig"}). The importance of a set of basic residues but lack of a specific requirement for any one of them individually suggest a need to maintain an overall basic charge on the GP~CL~ crest ([Fig. 3C](#fig3){ref-type="fig"}).

![The basic electrostatic potential of the GP~1~ crest is vital to receptor binding. (A) ELISA analysis of binding of wild-type or mutant GP~CL~ to NPC1 domain C. Replacement of positively charged K114 and K115 with neutral alanines or negatively charged glutamic acids reduces and abrogates NPC1 binding, respectively. Concomitant mutation of neighboring E112 and E120 to neutral alanine residues restores affinity for NPC1 domain C. Means ± SD (*n* = 4) from a representative experiment are shown. (B) Growth titers of VSV pseudotyped with electrostatic mutants of EBOV GP correlate with the NPC1 domain C affinities shown by the results in panel A: reduction in growth correlates with loss of positive charge. Means ± SD (*n* = 2--4) from a representative experiment are shown. (C) The electrostatic surface potential is calculated for each of the mutant EBOV GPs using APBS in PyMol (The PyMOL Molecular Graphics System, version 1.5.0.4. \[Schrödinger, LLC\], and APBS plugin for PyMol, M. G. Lerner and H. A. Carlson, University of Michigan, Ann Arbor, MI, 2006; 48). The view is looking down onto the EBOV GP trimer. Mutants with an overall negative charge on the surface of GP~1~ demonstrate defects in both affinity for NPC1 domain C and viral growth. See also [Fig. S1](#figS1){ref-type="supplementary-material"}, [S2](#figS2){ref-type="supplementary-material"}, and [S4](#figS4){ref-type="supplementary-material"} in the supplemental material.](mbo0011626960003){#fig3}

Neutralizing antibodies raised from a Marburg virus survivor demonstrate potential panfilovirus neutralization activity. {#s1.5}
------------------------------------------------------------------------------------------------------------------------

The high degree of sequence and structural conservation in the NPC1-binding site of filovirus glycoproteins makes it an attractive target for the development of broadly neutralizing MAbs with therapeutic potential (see [Fig. S3](#figS3){ref-type="supplementary-material"} in the supplemental material). Unfortunately, no such MAbs against ebolaviruses have been isolated. Instead, most known neutralizing anti-ebolavirus MAbs target a conformational epitope at the base of the GP~1,2~ trimer ([@B4], [@B5], [@B30], [@B31]). Recently, however, several MAbs isolated from a human survivor of MARV infection were found to recognize the hydrophobic GP~CL~ trough and inhibit GP-NPC1 domain C binding ([@B11], [@B22]). Of significance, one anti-MARV MAb from that study, MR72, cross-reacts with purified GP and GP~CL~ of EBOV, while three other MAbs, MR78, MR111, and MR191, cross-react only with EBOV GP~CL~ ([@B22]). MR72, MR78, MR111, and MR191 bind to similar locations on MARV GP but approach from significantly different angles ([@B22]). The third complementarity-determining region of the heavy chain variable region (CDRH3) of MR78 binds into the expected MARV GP~1~ RBS (see [Fig. S3](#figS3){ref-type="supplementary-material"}) ([@B11]).

As the RBS is conserved in sequence and structure across known filoviruses, we evaluated the capacity of MR72 and two additional GP~CL~-reactive antibodies, MR78 and MR191 ([@B22]), to recognize and neutralize VSV bearing GP~CL~ from four ebolaviruses (Sudan virus \[SUDV\], Bundibugyo virus \[BDBV\], Taï Forest virus \[TAFV\], and Reston virus \[RESTV\]) and the cuevavirus Lloviu virus (LLOV) ([@B2], [@B32]). Remarkably, we find that MR72 effectively neutralizes VSVs pseudotyped with GP~CL~ derived from all known filoviruses ([Fig. 4A](#fig4){ref-type="fig"}). In contrast, MR191 neutralizes VSV bearing other filovirus GPs only weakly, and MR78 fails to neutralize VSVs bearing GP~CL~ derived from any species other than MARV. We speculate that the steeper angle of approach of MR191 to MARV GP~CL~ compared to that of MR78 may enhance the breadth of neutralization by improving access to the shared RBS ([Fig. 4A](#fig4){ref-type="fig"} and [S3](#figS3){ref-type="supplementary-material"}). Of significance, we found that MR72 failed to bind VSVs bearing uncleaved EBOV GP on the surface (see [Fig. S3](#figS3){ref-type="supplementary-material"} in the supplemental material). This finding is in contrast to a previous observation of MR72 binding to uncleaved soluble EBOV GP ectodomain (see [Fig. S3](#figS3){ref-type="supplementary-material"}) ([@B22]). It is likely that there are differences in the presentation of EBOV GP on the surface of actual virions that prevent MR72 from binding and effectively neutralizing either wild-type EBOV or VSV bearing uncleaved EBOV GP.

![Monoclonal antibodies targeting the conserved GP~1~ RBS demonstrate panfilovirus neutralization activity. (A) VSV pseudotyped with GPs from different species of filovirus (as indicated in the key to the right) were preprimed with thermolysin to expose the GP~1~ RBS and then analyzed for reduction in relative infectivity following treatment with MR72 or MR78. (B) The graph to the left shows a comparative analysis of the neutralization of VSV-EBOV GP~CL~ and VSV-EBOV GP~CL~-V79A by MR72 and MR78. The graph to the right displays the results of competitive binding assays detecting NPC1 domain C binding in the presence of increasing concentrations of MR72 or MR78 for EBOV GP~CL~ and EBOV GP~CL~-V79A. The key for both graphs is on the far right. (C) Graph showing the results of comparative infectivity assays of nonprimed VSV pseudotyped with EBOV GP treated with MAbs from the ZMapp cocktail (2G4, 4G7, and 13C6) ([@B33]) or the neutralizing EBOV antibody KZ52 ([@B21]). MR72 neutralizes primed EBOV GP~CL~ pseudovirions at \>10-fold lower concentrations than are required for ZMapp or KZ52 to neutralize EBOV GP pseudovirions. See also [Fig. S3](#figS3){ref-type="supplementary-material"} in the supplemental material. Means ± SD (*n* = 2−4) from a representative experiment are shown in each panel.](mbo0011626960004){#fig4}

The contrasting neutralization breadth properties of MR72 and MR78, despite their similar binding angles and shared epitope, led us to explore our panel of GP~CL~ mutations to identify specific residues in the GP RBS that can affect MR78's neutralization of EBOV GP~CL~ (see [Fig. S2](#figS2){ref-type="supplementary-material"} in the supplemental material). We find that a single point mutation, V79A, allows MR78 to neutralize EBOV GP~CL~: although MR78 cannot neutralize VSV bearing wild-type EBOV GP~CL~, it can neutralize V79A-bearing VSV-EBOV GP~CL~ ([Fig. 4B](#fig4){ref-type="fig"}). Position 79 in EBOV GP is equivalent to position 63 in MARV. Structural alignment of EBOV GP~CL~ with MARV in the MARV GP-MR78 crystal structure ([@B11]) suggests that the wild-type V79 may sterically clash with the light chain of MR78. Replacement of valine with the smaller alanine residue (V79A) may improve neutralization by relieving the steric clash ([Fig. 4B](#fig4){ref-type="fig"}).

Furthermore, previous studies have shown that, unlike MR72, MR78 fails to block NPC1 domain C binding to EBOV GP~CL~ ([@B11]). Therefore, we performed NPC1 domain C competitive-binding assays to determine whether MR78 neutralizes EBOV GP~CL~-V79A by inhibiting GP-NPC1 binding. Curiously, even though MR78 is now able to neutralize VSV bearing EBOV GP~CL~-V79A, it remains unable to prevent binding of NPC1 domain C to EBOV GP~CL~ or EBOV GP~CL~-V79A ([Fig. 4B](#fig4){ref-type="fig"}). MR72, however, does block NPC1 binding to EBOV GP~CL~. Therefore, our data suggest that MAbs MR72 and MR78 may neutralize by distinct mechanisms. MR72 effectively blocks GP~CL~-NPC1 binding for all filoviruses, whereas MR78 does not block EBOV GP~CL~-NPC1 binding. We speculate that MR78 neutralizes EBOV entry by inhibiting viral membrane fusion downstream from virus receptor recognition.

In order to gauge the neutralization potentials of MR72 and MR78 relative to those of other MAbs with demonstrated protective efficacy *in vivo*, we performed a comparative analysis with the combined MAbs of the EBOV-specific ZMapp cocktail: 2G4, 4G7, and 13C6 ([@B31], [@B33]), as well as with KZ52, a known neutralizing MAb from a human survivor ([@B21]). Our analysis demonstrates that MR72 can neutralize pseudoviruses at 10-fold lower concentrations of antibody than are required for KZ52 and the ZMapp cocktail ([Fig. 4C](#fig4){ref-type="fig"}). Thus, MAbs such as MR72, which target the highly conserved GP~1~ RBS, represent a novel avenue for both broad and potent neutralization of filoviruses, if they can be delivered to the endosomal compartments where GP~CL~ is generated during entry.

DISCUSSION {#h2}
==========

In this study, we present the 3.3-Å crystal structure of thermolysin-cleaved EBOV GP (GP~CL~), which is primed for interaction with the filovirus receptor, NPC1. Thermolysin has previously been demonstrated to mimic host CatB and CatL proteolytic processing of EBOV GP, which occurs in the endosome and is required for receptor binding and membrane fusion ([@B8][@B9][@B10], [@B16]). This high-resolution structure of EBOV GP~CL~ has now defined the intermolecular disulfide bridge between C53 in GP~1~ and C609 in GP~2~, a region previously unresolved for EBOV GP. The disulfide bridge likely contributes to the inherent stability of ebolavirus GP despite proteolytic processing. This stability is reflected in a high degree of structural conservation between uncleaved EBOV GP ([@B4]) and GP~CL~; the aligned structures have an RMSD of 0.419 Å. The crystal structure of EBOV GP~CL~ presented here also illustrates how proteolytic priming removes the glycan cap of EBOV GP~1~ to expose the binding site for the filovirus receptor NPC1. The GP~CL~ crystal structure suggests that the glycan cap may act as a final layer of defense, shielding the critical and conserved NPC1 domain C binding site from host immune surveillance prior to cellular entry. We show that this RBS has a crest-and-trough morphology and exists at the apex of the GP~CL~ trimer.

The crest is lined with hydrophilic basic residues, while the trough is recessed and entirely hydrophobic. Mutagenic analysis of EBOV GP~CL~ demonstrates that the crest is involved in nonspecific electrostatic interactions with NPC1, requiring an overall basic charge to facilitate binding of NPC1 domain C. Mutations in EBOV GP (such as K114E+K115E) that reverse the electrostatic charge on the GP~CL~ crest consistently abrogate receptor binding and reduce infectivity. In contrast, the GP~CL~ trough is involved in more specific hydrophobic interactions with NPC1 domain C. Structure-based mutants with mutations designed to obstruct the structure of the trough (such as T83M+I113M) diminish the affinity of GP for NPC1 domain C and severely restrict the infectivity of VSV pseudotypes bearing these mutations. Based on the crystal structure and results of mutagenesis reported here, we propose that the NPC1 receptor binds GP in a two-stage process. First, GP~CL~ recruits the NPC1 domain C receptor through nonspecific electrostatic interactions between NPC1 and the basic crest region on GP~CL~. Without this interaction, there is no detectable GP-receptor binding. Next, specific hydrophobic interactions are initiated between the GP~1~ RBS trough and NPC1 domain C. The specificity of these interactions likely explains the differential effects of individual mutations in the trough ([Fig. 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}), whereas the effects of mutations in the crest were determined by charge, not specific amino acid position.

We also further analyzed two mutants with a mutation in the hydrophobic trough, F88A or L111A, which have been described previously as unable to support infection ([@B25], [@B26]). These two mutants are outliers in our analysis. Their infectivities are reduced by more than three log~10~ infectious units relative to that of WT EBOV GP, despite only modest defects in binding of NPC1 domain C. We postulate that these mutants are defective at a step downstream from NPC1 binding. They will provide useful tools to further decipher precisely how GP~CL~-NPC1 binding facilitates fusion triggering and membrane fusion.

Recent work has identified multiple neutralizing MAbs from a patient who survived MARV infection. The MAbs from those studies were found to bind to the apex of MARV GP~1~ ([@B11], [@B22])---the site we have confirmed here to be the filovirus GP~1~ receptor-binding site. Since ebolavirus, marburgvirus, and cuevavirus GP proteins all use the NPC1 protein as a receptor, it is not unexpected that the structure of the GP~1~ RBS would be highly conserved across all filoviruses ([@B10], [@B17][@B18][@B19], [@B32]). Thus, we hypothesized that the MAbs identified by Flyak et al. ([@B22]), shown to target the RBS trough on MARV GP~1~ ([@B11]), should be broadly neutralizing. However, unlike the GP proteins of marburgviruses, those of the ebolaviruses and cuevavirus maintain a glycan cap structure that effectively shields the GP~1~ RBS from immune surveillance. Therefore, by proteolytically priming filovirus GPs on the surface of VSV particles (such as VSV-EBOV GP~CL~), we were able to analyze the neutralization potential of MAbs targeting the otherwise-occluded filovirus RBS. Analysis of GP~CL~-bearing VSVs would tell us if it was worthwhile to target such antibodies to the endosome as future therapeutics.

Of the panel of neutralizing MAbs from an MARV survivor described by Flyak et al. ([@B22]), only one, MR72, demonstrates significant cross-reactivity to uncleaved EBOV GP. Three other MAbs, MR78, MR111, and MR191, only react with EBOV GP~CL~. We focused our analysis on the EBOV GP-reactive MR72 and the EBOV GP~CL~-reactive MR78 and MR191, which approach GP from different angles. Here, we show that MR72 effectively neutralizes VSV pseudovirions bearing GP~CL~ from EBOV, SUDV, BDBV, TAFV, RESTV, or LLOV. MR191 neutralizes the EBOV, BDBV, TAFV, and LLOV VSV-GP~CL~ virions weakly (and RESTV and SUDV GP~CL~ not at all), with infectivity never reduced below 50% (see [Fig. S3](#figS3){ref-type="supplementary-material"} in the supplemental material). In contrast, MR78 can only neutralize MARV GP~CL~. It cannot neutralize EBOV GP~CL~-bearing VSVs, even though it is able to bind them.

The crystal structures of MARV GP~CL~ and EBOV GP~CL~ bound to MR78 suggest that MR78 binds the same site in both viruses. However, the resolution of the EBOV GP~CL~-MR78 complex was too low to identify subtle differences imposed by sequence deviations from MARV GP that might explain why MR78 fails to neutralize EBOV GP~CL~ ([@B11]). Hence, we used a panel of VSV-EBOV GP RBS mutants to understand which sequence variations could prevent MR78-mediated neutralization of EBOV GP~CL~. Surprisingly, the introduction of a single point mutation (V79A) within the EBOV RBS allows MR78 to neutralize VSV-EBOV GP~CL~-V79A. Of significance, BDBV, TAFV, and RESTV GPs also encode valine at this position, while SUDV and LLOV GPs encode isoleucine and leucine, respectively. The larger Val, Ile, and Leu aliphatic residues encoded by the ebolaviruses and cuevavirus may prevent MR78 from neutralizing their GP~CL~-bearing particles ([Fig. 4A](#fig4){ref-type="fig"}; see also [Fig. S3](#figS3){ref-type="supplementary-material"} in the supplemental material). We note that, unlike MR78, MR191 exhibits no improvement in neutralization of VSV-EBOV GP~CL~-V79A (see [Fig. S3](#figS3){ref-type="supplementary-material"} in the supplemental material). How MR72 but not MR78 is able to overcome divergent amino acids at position 79 to broadly neutralize filovirus GP~CL~ is the subject of continued structural and biochemical study.

Remarkably, enhanced neutralization of EBOV GP~CL~-V79A by MR78 was not accompanied by a commensurate increase in its capacity to block NPC1 binding of this GP ([Fig. 4](#fig4){ref-type="fig"}). This apparent uncoupling of neutralization and receptor blockage raises the possibility that MR78 may act as an allosteric inhibitor, preventing membrane fusion by binding to GP~1~ subunits in the trimer that are not occupied by NPC1 domain C in the endosome. There, it may inhibit events that occur after receptor binding in order to trigger GP-mediated membrane fusion. Mutations like L111A, which eliminate infectivity without affecting receptor binding, may target these same post-receptor-binding steps.

Recent events, including the unprecedented EBOV epidemic in West Africa ([@B3], [@B34]), coinciding with human cases of MARV emerging in central Africa ([@B35]) and the emergence of BDBV ([@B36]) and re-emergence of SUDV ([@B37]) in this decade, highlight the urgent need for broad-spectrum antifilovirus therapeutics ([@B38]). Here, we demonstrate that the highly conserved binding site for the essential intracellular receptor NPC1 provides an attractive and underexplored target for broadly protective antibodies or small-molecule therapeutics. However, one crucial challenge to the development of such antibodies as therapeutics is an evolved feature of the filovirus entry mechanism---the unavailability of its NPC1-binding site to extracellular antibodies. The success of this antiviral strategy therefore requires novel protein engineering approaches to deliver GP~CL~-specific MAbs to late endosomes and/or lysosomes, where the NPC1-binding site is unmasked by host proteases.

MATERIALS AND METHODS {#h3}
=====================

Expression and purification of GP~CL~-KZ52 complex for crystallization. {#s3.1}
-----------------------------------------------------------------------

Ebola virus GP (lacking the mucin domain \[residues 312 to 462\]) was produced by stable expression in *Drosophila melanogaster* S2 cells. Briefly, Effectene (Qiagen) was used to transfect S2 cells with a modified pMT-puro vector plasmid containing the GP gene of interest, followed by stable selection of transfected cells with 6 µg/ml puromycin. Cells were cultured at 27°C in complete Schneider's medium for selection and then adapted to Insect Xpress medium (Lonza) for large-scale expression in 2-liter Erlenmeyer flasks. Secreted GP ectodomain expression was induced with 0.5 mM CuSO~4~, and supernatant harvested after 4 days. Ebola virus GP was engineered with a double Strep-tag at the C terminus to facilitate purification using Strep-Tactin resin (2-1201-010) (Qiagen) and then further purified by Superdex 200 size exclusion chromatography (SEC) in 10 mM Tris-buffered saline (Tris-HCl, pH 7.5, 150 mM NaCl \[TBS\]). EBOV GP~CL~ was produced by incubation of 1 mg GP with 0.02 mg thermolysin overnight at room temperature in TBS containing 1 mM CaCl~2~ and purified by using Superdex 200 SEC. Trimeric EBOV GP~CL~ was then complexed with a KZ52 Fab fragment prior to crystallization as previously described ([@B4]).

Crystallization, data collection, and structure determinations. {#s3.2}
---------------------------------------------------------------

The purified EBOV GP~CL~-KZ52 Fab complex was concentrated to 3.5 mg/ml in TBS. The crystal drops consisted of a 1:1 ratio of protein/well solution. The well solution consisted of 25% polyethylene glycol monomethyl ether 550 (PEG MME 550), 10% 2-propanol, 5% ethylene glycol, 100 mM sodium acetate, pH 4.7, and 100 mM calcium chloride. Crystals grew over the course of a month and were flash frozen directly out of the crystal drop into liquid nitrogen for data collection. Data were collected remotely at the Argonne National Laboratory, Advanced Photon Source (APS), from the GM/CA beamline 23-ID-D. The structure was determined using molecular replacement with PHASER ([@B39]), within the CCP4 suite ([@B40]), using a modified EBOV GP-KZ52 complex model (PDB code [3CSY](3CSY)) with all the residues corresponding to the glycan cap removed ([@B4]). Refinement of the EBOV GP~CL~ crystal structure was done through iterative cycles of model building using COOT, followed by refinement with Refmac5 and PHENIX ([@B41][@B42][@B43]). Translation/libration/screw (TLS) motion was applied during refinement with the TLS Motion Determination (TLSMD) server used to determine the TLS structure partitions ([@B44], [@B45]). Five percent of the data was set aside prior to refinement for the *R*~free~ calculations for each data set ([@B46]). The statistics and stereochemistry of the crystal structure were checked using the MolProbity server until ranking at least at the \>95th percentile (see [Fig. S2A](#figS2){ref-type="supplementary-material"} in the supplemental material) ([@B47]). All of the structural figures were rendered using PyMOL (PyMOL Molecular Graphics System, version 1.5.0.4; Schrödinger, LLC).

Cells and viruses. {#s3.3}
------------------

African grivet monkey kidney (Vero) cells were maintained at 37°C and 5% CO~2~ in high-glucose Dulbecco's modified Eagle medium (DMEM; Invitrogen Corp., Carlsbad, CA) supplemented with 10% fetal calf serum. Replication-incompetent vesicular stomatitis virus (VSV) (serotype Indiana) pseudotyped viruses were generated as previously described ([@B49]). The wild type (VSV-WT GP) encodes enhanced green fluorescence protein (eGFP) in place of the VSV-G gene to allow scoring of infection and bears the EBOV GPΔmuc gene (Mayinga isolate, GenBank accession number [AF086833](AF086833)) but lacks the mucin-like domain (residues 309 to 489 \[Δmuc\]) ([@B6]). Point mutants and multiple mutants were generated by subcloning GP fragments containing the mutation(s) to replace EBOV GPΔmuc. Cleaved VSV-GP~CL~ particles were generated by incubating VSV-GP pseudotypes with thermolysin (250 µg/ml) for 1 h at 37°C. The reaction was stopped by adding phosphoramidon (1 mM) and incubating on ice for 5 min.

Normalization of GP for ELISA. {#s3.4}
------------------------------

Normalization of GP~CL~ amounts to be used in the binding experiments was done by ELISA, as illustrated in [Fig. S4](#figS4){ref-type="supplementary-material"} in the supplemental material. Briefly, high-binding 96-well ELISA plates (Corning) were coated with serial dilutions of GP~CL~ in phosphate-buffered saline (PBS), and allowed to bind at 37°C for 1 h. The plates were blocked with PBS containing 3% bovine serum albumin (PBSA), followed by incubation with the anti-GP monoclonal antibody KZ52 (2 µg/ml in PBS) ([@B21]) and a horseradish-conjugated anti-human secondary antibody (Santa Cruz Biotechnology), which was detected by ultra-TMB (3,3′,5,5′-tetramethylbenzidine) substrate (Thermo Scientific). Absorbance readings were subjected to a nonlinear regression analysis (GraphPad Prism software) to generate binding curves and calculate an EC~50~ value. Additionally, the virions were normalized for GP incorporation by comparing the amount of GP to the amount of the VSV matrix protein (M). Equal amounts of purified virions were resolved on SDS-PAGE and blotted for the VSV matrix protein using a mouse anti-VSV M antibody (23H12). Quantification was done using a LI-COR IR dye-conjugated anti-mouse Alexa Fluor 680 secondary antibody (Invitrogen) on the Odyssey Imaging Station and Image Studio 2.1 software (LI-COR Biosciences), and the results were normalized to the WT control. Virus particles that had less than 25% incorporation of mutant GP compared to the incorporation of WT GP or that were highly sensitive to proteolysis were excluded from our analysis.

GP-NPC1 domain C capture ELISA. {#s3.5}
-------------------------------

Binding of GP to NPC1 domain C was performed as previously described ([@B10], [@B32]). Briefly, high-binding 96-well ELISA plates (Corning) were coated with the anti-GP monoclonal antibody KZ52 (2 µg/ml in PBS) ([@B21]). Following a blocking step, either uncleaved or *in vitro*-cleaved GP~CL~ pseudotypes were captured on the plate. Unbound GP was washed off, and serial dilutions of Flag-tagged purified soluble human NPC1 domain C (0 to 40 µg/ml) were added. Bound NPC1 domain C was detected by a horseradish-conjugated anti-Flag antibody (Sigma-Aldrich), using ultra-TMB substrate (Thermo Scientific). EC~50~s were calculated from binding curves generated by nonlinear regression analysis using GraphPad Prism software. Binding ELISAs were done in duplicate in at least two independent experiments. All incubation steps were done at 37°C for 1 h or at 4°C overnight.

Pseudovirus neutralization assays. {#s3.6}
----------------------------------

Serial dilutions of MAbs and of a no-antibody control were mixed with either cleaved or uncleaved VSV-GP particles and allowed to bind for 1 h at room temperature. Monolayers of Vero cells were inoculated with the antibody-virus mixture in duplicate and incubated at 37°C in 5% CO~2~. Infection was scored 12 to 16 h postinfection by enumeration of eGFP-positive cells under a fluorescence microscope. The ZMapp cocktail MAbs 2G4, 4G7, and 13C6, as well as MAb KZ52, prepared as previously described ([@B33]), were generously provided by Mapp Biopharmaceutical. MAbs MR78 and MR72 were prepared as previously described ([@B22]).

Protein structure accession number. {#s3.7}
-----------------------------------

Coordinates and structure factors have been deposited into the Protein Data Bank under accession number [5HJ3](http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HJ3).

SUPPLEMENTAL MATERIAL {#sm1}
=====================
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This figure is related to [Fig. 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}. Heat maps of point mutations made to EBOV GP. The EBOV GP~CL~ structure is shown centered on GP~1~. (A) Heat map of single point mutations (see [Fig. S2A](#figS2){ref-type="supplementary-material"} in the supplemental material) that are colored relative to their effect on viral infectivity. Mutations of residues colored green have no measurable effect, mutations of residues colored orange have a moderate effect, and mutations of residues colored red have a severe defect. (B) Heat map of single point mutations (see [Fig. S2A](#figS2){ref-type="supplementary-material"}) that are colored relative to their effect on NPC1 domain C affinity. The locations and identities of residues having moderate or severe effects are labeled in each panel. Download
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Figure S1, PDF file, 2.7 MB
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This figure is related to [Fig. 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}. Complete panel of EBOV GP mutations and incorporation of relevant GP mutants into pseudoviruses. (A) The complete panel of VSV pseudotyped EBOV GP mutants is shown, with the viral incorporation level, measured infectivity (in duplicate), and NPC1 binding avidity (in duplicate) for each mutant pseudovirus relative to those of the wild type. (B and C) Levels of EBOV GP incorporation into VSV pseudotyped viruses for mutants discussed in Results. Data are normalized to 100% incorporation of WT EBOV GP. Of note, despite significant defects in incorporation, the K114R+K115R double mutant maintains close to wild-type levels of infectivity ([Fig. 3](#fig3){ref-type="fig"}). This mutation maintains the positive charge of positions 114 and 115. Download
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Figure S2, PDF file, 0.3 MB

###### 

This figure is related to [Fig. 4](#fig4){ref-type="fig"}. Targeting the conserved filovirus receptor-binding site in GP~1~ with a neutralizing antibody. (A) Sequence alignment of the residues that comprise the filovirus GP~1~ RBS shows significant conservation across all known filovirus species. The alignment is broken up into the three blocks of conservation, each spanning a series of residues that make up the filovirus GP~1~ RBS. The colored bars below each block of sequence signify the coloring used in panel B to map these blocks of sequence onto the EBOV GP~CL~ crystal structure. (B) The crystal structure of MR78 bound to EBOV GP~CL~ is shown. Only one MR78 antibody fragment (colored purple) is displayed, for simplicity. The MR78 CDRH3 (colored hot pink) reaches into the EBOV GP~CL~ RBS and interacts with residues from each block of conserved sequence from panel A, demonstrating how MAbs targeting the GP~1~ RBS could cross-react among the filoviruses. (C) Binding and infectivity curves of MR72 and MR78 targeting either VSV bearing uncleaved EBOV GP or EBOV GP~CL~. (D) MR191 also targets the conserved GP~1~ RBS and demonstrates panfilovirus neutralization activity. Preprimed VSVs pseudotyped with the GPs from different species of filovirus (as indicated in the key to the right) were analyzed for reduction in relative infectivity following treatment with MR191. Neutralization of VSV-EBOV GP by MR72 ([Fig. 4](#fig4){ref-type="fig"}) is included for comparison. (E) Neutralization of VSV-EBOV GP~CL~-V79A and VSV-MARV GP~CL~ by MR191. Unlike MR78, MR191 does not benefit from the V79A mutation to EBOV GP, showing only a slight reduction in infectivity in comparison to that of VSV-EBOV GP~CL~ (as indicated in the key to the right). Download
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Figure S3, PDF file, 1.2 MB
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This figure is related to [Fig. 2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, and [4](#fig4){ref-type="fig"}. Quality control workflow for VSV-GP pseudotypes. (A) A GP ELISA was used to normalize concentrated VSV-GP preparations for GP~CL~ content. ELISA titration curves were fit to a 4-parameter logistic equation, and EC~50~s were used to adjust the volumes of viral particles used for GP-NPC1 binding studies, as shown. **(**B) GP incorporation into viral particles. Briefly, the relative number of viral particles in each mutant preparation (compared to WT) was determined by gel band densitometry of the internal VSV matrix protein (M). This M content ratio (a measure of relative particle numbers) was used to normalize GP content from the data shown in panel A and estimate GP incorporation (relative to that of the WT). Download

###### 

Figure S4, PDF file, 0.2 MB
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